Cargando…

Cancer T-cell therapy: building the foundation for a cure

T-cell cancer therapy is a clinical field flush with opportunity.  It is part of the revolution in immuno-oncology, most apparent in the dramatic clinical success of PD-1/CTLA-4 antibodies and chimeric antigen receptor T-cells (CAR-Ts) to cure certain melanomas and lymphomas, respectively.  Therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamb, Alexander, Go, William Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713893/
https://www.ncbi.nlm.nih.gov/pubmed/33335718
http://dx.doi.org/10.12688/f1000research.27217.2
_version_ 1783618638999191552
author Kamb, Alexander
Go, William Y.
author_facet Kamb, Alexander
Go, William Y.
author_sort Kamb, Alexander
collection PubMed
description T-cell cancer therapy is a clinical field flush with opportunity.  It is part of the revolution in immuno-oncology, most apparent in the dramatic clinical success of PD-1/CTLA-4 antibodies and chimeric antigen receptor T-cells (CAR-Ts) to cure certain melanomas and lymphomas, respectively.  Therapeutics based on T cells ultimately hold more promise because of their capacity to carry out complex behaviors and their ease of modification via genetic engineering.  But to overcome the substantial obstacles of effective solid-tumor treatment, T-cell therapy must access novel molecular targets or exploit existing ones in new ways.  As always, tumor selectivity is the key. T-cell therapy has the potential to address target opportunities afforded by its own unique capacity for signal integration and high sensitivity.  With a history of breathtaking innovation, the scientific foundation for the cellular modality has often been bypassed in favor of rapid advance in the clinic.  This situation is changing, as the mechanistic basis for activity of CAR-Ts and TCR-Ts is backfilled by painstaking, systematic experiments—harking back to last century’s evolution and maturation of the small-molecule drug discovery field.   We believe this trend must continue for T-cell therapy to reach its enormous potential.  We support an approach that integrates sound reductionist scientific principles with well-informed, thorough preclinical and translational clinical experiments.
format Online
Article
Text
id pubmed-7713893
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-77138932020-12-16 Cancer T-cell therapy: building the foundation for a cure Kamb, Alexander Go, William Y. F1000Res Opinion Article T-cell cancer therapy is a clinical field flush with opportunity.  It is part of the revolution in immuno-oncology, most apparent in the dramatic clinical success of PD-1/CTLA-4 antibodies and chimeric antigen receptor T-cells (CAR-Ts) to cure certain melanomas and lymphomas, respectively.  Therapeutics based on T cells ultimately hold more promise because of their capacity to carry out complex behaviors and their ease of modification via genetic engineering.  But to overcome the substantial obstacles of effective solid-tumor treatment, T-cell therapy must access novel molecular targets or exploit existing ones in new ways.  As always, tumor selectivity is the key. T-cell therapy has the potential to address target opportunities afforded by its own unique capacity for signal integration and high sensitivity.  With a history of breathtaking innovation, the scientific foundation for the cellular modality has often been bypassed in favor of rapid advance in the clinic.  This situation is changing, as the mechanistic basis for activity of CAR-Ts and TCR-Ts is backfilled by painstaking, systematic experiments—harking back to last century’s evolution and maturation of the small-molecule drug discovery field.   We believe this trend must continue for T-cell therapy to reach its enormous potential.  We support an approach that integrates sound reductionist scientific principles with well-informed, thorough preclinical and translational clinical experiments. F1000 Research Limited 2020-12-22 /pmc/articles/PMC7713893/ /pubmed/33335718 http://dx.doi.org/10.12688/f1000research.27217.2 Text en Copyright: © 2020 Kamb A and Go WY http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Opinion Article
Kamb, Alexander
Go, William Y.
Cancer T-cell therapy: building the foundation for a cure
title Cancer T-cell therapy: building the foundation for a cure
title_full Cancer T-cell therapy: building the foundation for a cure
title_fullStr Cancer T-cell therapy: building the foundation for a cure
title_full_unstemmed Cancer T-cell therapy: building the foundation for a cure
title_short Cancer T-cell therapy: building the foundation for a cure
title_sort cancer t-cell therapy: building the foundation for a cure
topic Opinion Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713893/
https://www.ncbi.nlm.nih.gov/pubmed/33335718
http://dx.doi.org/10.12688/f1000research.27217.2
work_keys_str_mv AT kambalexander cancertcelltherapybuildingthefoundationforacure
AT gowilliamy cancertcelltherapybuildingthefoundationforacure